Shelf life (days): 1460.0
Formulation: A solid
Formal Name: (aR)-a-[[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]oxy]-2-pyrimidinepropanoic acid, 1-methylethyl ester
Purity: ≥98%
Formula Markup: C23H27N3O4
Formula Weight: 409.5
CAS Number: 2272917-13-0
Notes: NT-0796 is an inhibitor of the NOD-like receptor protein 3 (NLRP3) inflammasome and a prodrug form of NDT-19795.{69867} It selectively inhibits NLRP3 over NLR family CARD domain-containing protein 4 (NLRC4) at 3 nM, as well as a panel of 121 other receptors at 10 µM, but does inhibit the serotonin (5-HT) receptor subtype 5-HT2B by 90% at 10 µM. NT-0796 inhibits LPS- and ATP-induced IL-1β release in isolated human peripheral blood mononuclear cells (PBMCs) and whole blood (IC50s = 0.32 and 6.8 nM, respectively), however, it does not affect LPS-induced TNF-α or IL-6 release in isolated human PBMCs (IC50s = >2 µM for both), indicating NLRP3 selectivity. It decreases body weight, food intake, and plasma levels of total cholesterol, HDL, and proprotein convertase subtilisin kexin type 9 (PCSK9) in a model of high-fat diet-induced obesity using transgenic mice expressing human carboxylesterase-1 (CES1), the enzyme that converts NT-0796 to NDT-19795, when administered at a dose of 100 mg/kg three times per day.{69868}
Deutsch
English
